BrightSpring Health Services reported second-quarter earnings of 45 cents per share, exceeding analyst expectations for the period ending in July 2026 [1].
The results signal a period of aggressive expansion for the NASDAQ-listed company, driven largely by its pharmacy and home health sectors. This growth has allowed the firm to increase its financial outlook for the remainder of the year while targeting debt reduction.
Earnings per share for the second quarter reached 45 cents [1], which represents a 13% beat over estimates [5]. This is a significant increase from the 22 cents per share reported during the same quarter in 2025 [3]. The Zacks Consensus EPS estimate had previously projected 37 cents per share [2].
Revenue growth also showed a strong upward trend. The company saw a 23% increase in revenue year-over-year [4], which outperformed expectations by 5.7% [6]. Much of this momentum came from the Provider Services and Pharmacy Solutions businesses [11, 12].
Specific operational gains contributed to the bottom line. Pharmacy profit per prescription saw a 28% jump [7], a metric that underscores the efficiency of the company's pharmaceutical wing. Additionally, home health services experienced a 54% surge [8].
Following these results, BrightSpring raised its full-year adjusted EBITDA guidance for 2026 to a range between $820 million and $845 million [9]. The company said it is targeting a leverage ratio below 2x [10].
“Earnings per share for the second quarter reached 45 cents”
The combination of a significant earnings beat and raised guidance suggests that BrightSpring is successfully scaling its specialized health services. By targeting a leverage ratio below 2x, the company is prioritizing balance sheet health alongside operational growth, likely to improve its valuation and credit standing in the U.S. healthcare market.
